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OBJECTIVE—The insulinotropic action of the incretin glucose-
dependent insulinotropic polypeptide (GIP) is impaired in type 2
diabetes, while the effect of glucagon-like peptide-1 (GLP-1) is
preserved. To evaluate the role of impaired GIP function in
glucose homeostasis and development of the endocrine pancreas
in a large animal model, we generated transgenic pigs expressing
a dominant-negative GIP receptor (GIPR
dn) in pancreatic islets.
RESEARCH DESIGN AND METHODS—GIPR
dn transgenic
pigs were generated using lentiviral transgenesis. Metabolic tests
and quantitative stereological analyses of the different endocrine
islet cell populations were performed, and -cell proliferation
and apoptosis were quantiﬁed to characterize this novel animal
model.
RESULTS—Eleven-week-old GIPR
dn transgenic pigs exhibited
signiﬁcantly reduced oral glucose tolerance due to delayed
insulin secretion, whereas intravenous glucose tolerance and
pancreatic -cell mass were not different from controls. The
insulinotropic effect of GIP was signiﬁcantly reduced, whereas
insulin secretion in response to the GLP-1 receptor agonist
exendin-4 was enhanced in GIPR
dn transgenic versus control
pigs. With increasing age, glucose control deteriorated in GIPR
dn
transgenic pigs, as shown by reduced oral and intravenous
glucose tolerance due to impaired insulin secretion. Importantly,
-cell proliferation was reduced by 60% in 11-week-old GIPR
dn
transgenic pigs, leading to a reduction of -cell mass by 35% and
58% in 5-month-old and 1- to 1.4-year-old transgenic pigs com-
pared with age-matched controls, respectively.
CONCLUSIONS—The ﬁrst large animal model with impaired
incretin function demonstrates an essential role of GIP for
insulin secretion, proliferation of -cells, and physiological ex-
pansion of -cell mass. Diabetes 59:1228–1238, 2010
T
he incretin hormones glucose-dependent insuli-
notropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1) are secreted by enteroendo-
crine cells in response to nutrients like fat and
glucose and enhance glucose-induced release of insulin
from pancreatic -cells (1). The effects of GIP and GLP-1
are mediated through speciﬁc receptors, GIPR and GLP-
1R, respectively. Both receptors belong to the family of
seven transmembrane-domain heterotrimeric G-protein–
coupled receptors (2). Activation of the GIPR or GLP-1R
leads to enhanced exocytosis of insulin-containing gran-
ules (3). Interestingly, variation in the GIPR gene inﬂu-
ences glucose and insulin responses to an oral glucose
challenge in humans (4). Furthermore, ﬁndings in insuli-
noma cells (5–7) and rodent models (8,9) indicate that
activation of incretin receptors promotes proliferation and
survival of -cells. Type 2 diabetic patients and 50% of
their ﬁrst-degree relatives show a reduced incretin effect,
mainly due to an impaired insulinotropic action of GIP
(10,11). Nearly sustained insulinotropic action of GLP-1
(11) in type 2 diabetic patients revealed its therapeutic
potential and initiated the ongoing development of GLP-1R
agonists as well as inhibitors of dipeptidyl peptidase-4
(1,12), which rapidly degrades incretin hormones in vivo.
The reasons for the reduced response to GIP in type 2
diabetes are unclear (1), but impaired GIP action might be
involved in the early pathogenesis of type 2 diabetes (13).
To clarify this point, a mouse model lacking functional
GIPR expression was generated by gene targeting (14).
Gipr
/ mice displayed only slightly impaired glucose
tolerance and did not develop diabetes. Interestingly,
double incretin receptor knockout mice exhibited a simi-
lar phenotype. As possible explanations for this relatively
mild phenotype (rev. in 15), compensatory regulation of
the GLP-1 system or other compensatory mechanisms
were discussed. In contrast, transgenic mice overexpress-
ing a dominant-negative GIPR (GIPR
dn) displayed a severe
phenotype (i.e., early-onset diabetes accompanied by a
marked fasting hypoinsulinemia and severe reduction of
-cell mass associated with extensive structural alter-
ations of the pancreatic islets) (16).
In light of these discrepant ﬁndings in mouse models,
we generated a large animal model to address the question
whether GIPR signaling plays a role in maintaining pan-
creatic islet function and structure. Efﬁcient lentiviral
vectors (17) were used to generate transgenic pigs ex-
pressing a GIPR
dn under the control of the rat Ins2
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in contrast to GIPR
dn transgenic mice (16), initially only
exhibits a disturbed incretin effect but develops progres-
sive deterioration of glucose control with increasing age,
associated with reduced -cell proliferation and an impair-
ment of physiological age-related expansion of pancreatic
-cell mass.
RESEARCH DESIGN AND METHODS
Generation of RIP II-GIPR
dn transgenic pigs. The expression cassette
consisting of the rat Ins2 promoter (RIP II) and the cDNA of a human GIPR
dn
(16) was cloned into the lentiviral vector LV-pGFP (18) (supplementary Fig. 1
of the online appendix [available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0519/DC1]). Recombinant lentivirus was produced (18) and
injected into the perivitelline space of zygotes from superovulated gilts (17).
Embryos were transferred into synchronized recipients (19). Offspring were
genotyped by PCR and Southern blot analyses using a probe directed toward
the RIP II promoter sequence. Expression of GIPR
dn mRNA in the pancreatic
islets was determined by RT-PCR. A total of 400 ng of total RNA were reverse
transcribed into cDNA using SuperScriptII reverse transcriptase (Invitrogen)
and random hexamer primers (Invitrogen) after digestion with DNaseI
(Roche). For PCR, the following transgene speciﬁc primers were used: sense
5-TTT TTA TCC GCA TTC TTA CAC GG-3 and antisense 5-ATC TTC CTC
AGC TCC TTC CAG G-3. All animal experiments were carried out according
to the German animal protection law.
Oral/intravenous glucose tolerance test and GIP/exendin-4 stimulation
test. For the oral glucose tolerance test (OGTT), one central venous catheter
(Cavaﬁx Certo; B. Braun) was inserted nonsurgically into the external jugular
vein. After an 18-h overnight fast, animals were fed 2 g glucose/kg body weight
(BW) (20) mixed with 50/100 g (11-week-old/5-month-old) commercial pig
fodder. Blood samples were obtained from the jugular vein catheter at the
indicated time points. For the intravenous glucose tolerance test (IVGTT) and
GIP/exendin-4 stimulation test, two central venous catheters (Cavaﬁx Certo)
were surgically inserted into the external jugular vein under general anesthe-
sia (21). For both tests, a bolus injection of 0.5 g glucose/kg BW (22) was
administered through the central venous catheter after an 18-h fasting period.
For the GIP/exendin-4 stimulation test, 80 pmol/kg BW of synthetic porcine
GIP (Bachem) or 40 pmol/kg BW synthetic exendin-4 (Bachem) were admin-
istered intravenously in addition to glucose. Blood samples were collected at
the indicated time points. Serum glucose levels were determined using an AU
400 autoanalyzer (Olympus). Serum insulin levels were measured using a
porcine insulin radioimmunoassay kit (Millipore).
Pancreas preparation and islet isolation. Pancreatic islets were isolated
from three 12- to 13-month-old GIPR
dn transgenic pigs and three littermate
control animals (23). After explantation of the pancreas in toto, the left
pancreatic lobe was separated from the rest of the organ (supplementary Fig.
2). The left pancreatic lobe was digested using a modiﬁcation of the half-
automated digestion-ﬁltration method as previously described (24). Puriﬁca-
tion of the isolated islets was performed with the discontinuous OptiPrep
density gradient (Progen) in the COBE 2991 cell processor (COBE) (25). Islet
numbers were determined using dithizone-stained islet samples (26), which
were counted under an Axiovert 25 microscope (Zeiss) with a calibrated grid
in the eyepiece. For determination of islet vitality, ﬂuorescein diacetate/
propidium iodide (Sigma-Aldrich) staining was performed (27).
Immunohistochemistry and quantitative stereological analyses. After
preﬁxation, the pancreas was cut into 1-cm-thick slices. Slices were tilted to
their left side and covered by a 1-cm
2 point-counting grid. Tissue blocks were
selected by systematic random sampling, ﬁxed in 10% neutral buffered
formalin, routinely processed, and embedded in parafﬁn. The volume of the
pancreas [V(Pan)] before embedding was calculated by the quotient of the
pancreas weight and the speciﬁc weight of pig pancreas (1.07 g/cm
3).
The speciﬁc weight was determined by the submersion method (28). Parafﬁn
sections were routinely prepared, and insulin, glucagon, somatostatin, and
pancreatic polypeptide containing cells were stained, using the indirect
immunoperoxidase technique (16) and the antibodies described in the online
appendix. The volume densities of -, -, -, and pp-cells in the islets
[Vv(-cell/Islet), Vv(-cell/Islet), Vv(-cell/Islet), and Vv(pp-cell/Islet)], the total volumes of
-, -, -, and pp-cells in the islets [V(-cell, Islet), V(-cell, Islet), V(-cell, Islet), and
V
(pp-cell, Islet)] as well as the total volume of -cells in the pancreas [referring to
-cells in the islets and isolated -cells, V(-cell, Pan)], and the total volume of
isolated -cells in the pancreas [V(iso-cell, Pan)], a parameter indicative of islet
neogenesis (29–31), were determined as described previously (32). Volume
densities of the various endocrine cell types in the islets refer to the volume
fraction of the particular endocrine cell type in relation to the cumulative
volume of the various endocrine islet cells, thus excluding capillaries and
other interstitial tissues in the islets.
Proliferation/apoptosis rates of -cells were determined by double immu-
nohistochemical staining for insulin and the proliferation marker Ki67 (33) or
the apoptosis marker cleaved caspase-3 (34) as detailed in the online
appendix. A minimum of 10
4 -cells per animal was included in the quantiﬁ-
cation of -cell proliferation and apoptosis. Cell proliferation/apoptosis index
was deﬁned as the number of immunolabeled cell nuclei divided by the total
number of cell nuclei counted and expressed as the number of immunolabeled
(Ki67/Casp-3) cell nuclei per 10
5 nuclei. GIPR and GLP-1R were detected
in pancreas sections using the streptavidin-biotin complex technique and the
antibodies described in the online appendix.
Statistics. All data are presented as means  SE. The results of glucose
tolerance tests and incretin stimulation tests were statistically evaluated by
ANOVA (linear mixed models; SAS 8.2; PROC MIXED), taking the ﬁxed effects
of group (wild type, transgenic), time (relative to glucose or hormone
application), and the interaction group 	 time as well as the random effect of
animal into account (35). Results of the linear mixed models analysis are
shown in supplementary Table 1. The same model was used to compare body
weight gain of GIPR
dn transgenic and control pigs. Pancreas weight and the
results of quantitative stereological analyses were evaluated by the general
linear models procedure (SAS 8.2) taking the effects of group (wild type,
transgenic), age (11 weeks, 5 months, or 1–1.4 years), and the interaction
group 	 age into account. Results of the general linear models analysis are
shown in Table 1. Calculation of areas under the curve (AUCs) was performed
using Graph Pad Prism 4 software. Statistical signiﬁcance of differences
between transgenic and wild-type pigs was tested using the Mann-Whitney U
test in combination with an exact test procedure (SPSS 16.0, Chicago, IL). P
values 
0.05 were considered signiﬁcant.
RESULTS
Generation of GIPR
dn transgenic pigs. A lentiviral
vector was cloned that expresses a dominant-negative
GIPR (GIPR
dn) under the control of the rat insulin 2 gene
promoter (RIP II) (Fig. 1A). The GIPR
dn has an eight–
amino acid deletion (positions 319–326) and an Ala3Glu
exchange at amino acid position 340 in the third intracel-
lular loop, which is essential for signal transduction (16).
Lentiviral vectors were injected into the perivitelline space
of pig zygotes (17). A total of 113 injected zygotes were
transferred laparoscopically into the oviducts of three
cycle-synchronized recipient gilts. Nineteen piglets (17% of
the transferred zygotes) were born. Southern blot analysis
identiﬁed nine founder animals (47% of the born animals)
carrying one or two lentiviral integrants (Fig. 1B), conﬁrm-
ing the high efﬁciency of lentiviral transgenesis in large
animals (17).
Two male founder animals (nos. 50 and 51) were mated
to nontransgenic females (Fig. 1B). The resulting offspring
demonstrated germ line transmission and segregation of
the integrants according to Mendelian rules (Fig. 1B). To
analyze expression of GIPR
dn mRNA, pancreatic islets
were isolated from transgenic and nontransgenic offspring
and analyzed by RT-PCR. Expression of the GIPR
dn was
detected in the islets of all transgenic animals but not in
the islets of nontransgenic control animals (Fig. 1C).
GIPR
dn transgenic pigs developed normally and did not
show any deviation in body weight gain compared with
controls (Fig. 2).
Normal fasting glucose and fructosamine levels in
GIPR
dn transgenic pigs. To evaluate effects of GIPR
dn
expression on glucose homeostasis, fasting blood glucose
and serum fructosamine levels were determined in regular
intervals from 1 to 7 months of age. No signiﬁcant differ-
ences in blood glucose levels and serum fructosamine
levels were detected between GIPR
dn transgenic and con-
trol pigs (supplementary Fig. 3). Fasting blood glucose
levels, determined in irregular intervals up to an age of 2
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dn transgenic pigs (data not
shown).
Reduced insulinotropic effect of GIP but enhanced
insulinotropic effect of exendin-4 in GIPR
dn trans-
genic pigs. To evaluate whether expression of a GIPR
dn
speciﬁcally impairs the function of GIP, we performed
stimulation tests with GIP and the GLP-1 receptor agonist
exendin-4 (1). The insulinotropic effect of GIP, intrave-
nously administered as a bolus, was signiﬁcantly dimin-
ished (Fig. 3A), while insulin secretion in response to
exendin-4 was increased in GIPR
dn transgenic versus
control pigs (Fig. 3B), leading to a faster decrease of
serum glucose levels (Fig. 3D). These ﬁndings demon-
strate that expression of GIPR
dn speciﬁcally reduces the
insulinotropic action of GIP and does not impair the
function of a related G-protein–coupled receptor, namely
the GLP-1R. Further, the enhanced insulinotropic effect of
exendin-4 in GIPR
dn transgenic versus control pigs indi-
cates a compensatory hyperactivation of the GLP-1/
GLP-1R system, which has also been observed in Gipr
/
mice (rev. in 15). To clarify, whether compensatory mech-
anisms involve altered expression of incretin receptors,
we performed immunohistochemical staining of pancreas
sections for GIPR (Fig. 3E) and GLP-1R (Fig. 3F), which
revealed no apparent difference in the abundance and
spatial distribution of both receptors comparing GIPR
dn
transgenic and control pigs.
Disturbed incretin function in young GIPR
dn trans-
genic pigs. An OGTT (2 g glucose/kg BW) was performed
in 11-week-old GIPR
dn transgenic pigs (n  5) and con-
trols (n  5) originating from founder boars nos. 50 and
51. GIPR
dn transgenic pigs exhibited elevated (P 
 0.05)
serum glucose levels (Fig. 4A) as well as a distinct delay in
insulin secretion (Fig. 4B) after glucose challenge. The
area under the insulin curve (AUC insulin) during the ﬁrst
45 min following glucose challenge was 31% (P 
 0.05)
smaller in GIPR
dn transgenic pigs than in age-matched
controls (Fig. 4B); however, the total amount of insulin
secreted during the experimental period (i.e., total AUC
insulin until 120 min following glucose load) was not
different between the two groups (5,155  763 vs. 5,698 
625; P  0.351). These ﬁndings indicate that expression of
a GIPR
dn in the pancreatic islets of transgenic pigs is
sufﬁcient to interfere with the incretin effect but does not
initially affect the total AUC insulin. This assumption is
supported by the fact that intravenous glucose tolerance
was not reduced in GIPR
dn transgenic pigs (Fig. 5A), and
the time course and amount of insulin secreted in re-
sponse to an intravenous glucose load were not different
between the two groups (Fig. 5B). Quantitative stereologi-
cal investigations of the pancreas (32) revealed that the
total volume of -cells in the pancreas was not different
between GIPR
dn transgenic pigs and controls (Fig. 6A).
Further, the total volume of isolated -cells (single insulin-
positive cells and small clusters of insulin-positive cells
not belonging to established islets) was equal in the two
groups (49  4 vs. 49  6m m
3; P  0.695). These ﬁndings
FIG. 1. Lentiviral vector, Southern blot analyses, and transgene ex-
pression. A: The lentiviral vector (LV-GIPR
dn) carrying the cDNA of
the dominant-negative GIPR (GIPR
dn) under the control of the rat
Ins2 gene promoter (RIP II). ApaI, restriction site of ApaI; LTR, long
terminal repeat; ppt, polypurine tract; SIN, self-inactivating mutation;
W, woodchuck hepatitis posttranscriptional regulatory element; probe,
probe used for Southern blot analyses; wavy lines, pig genome. B:
Southern blot analyses of ApaI-digested genomic DNA isolated from
EDTA blood of piglets generated by subzonal injection of LV-GIPR
dn
(transgenic [tg]) and two nontransgenic littermates (wild type [wt]).
Pigs of the F0 generation show either one or two single-copy integra-
tion sites of the transgene. Sires 50 and 51 (S 50/S 51) were selected to
establish two transgenic lines. Note that pigs of the F1 generation show
segregation of the integrants according to the Mendelian rules. C:
Analysis of transgene expression (GIPR
dn) in isolated porcine islets of
Langerhans of transgenic (tg) and nontransgenic littermates (wt) by
RT-PCR. -Actin RT-PCR used for conﬁrmation of reverse transcrip-
tion efﬁciency. Due to the use of intron-spanning primers to detect
-actin, two different-sized bands are visible differentiating cDNA and
genomic DNA. M: pUC Mix Marker; RT wt: minus RT wild-type pigs;
RT tg: minus RT GIPR
dn transgenic pigs (no signals were obtained
from islets of transgenic offspring after omission of the RT step,
demonstrating that expressed rather than integrated sequences were
detected); , genomic DNA of GIPR
dn transgenic pig; , aqua bidest.
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FIG. 2. Body weight gain of GIPR
dn transgenic pigs (tg) compared with
control pigs (wt). Data are means  SE. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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FIG. 3. Functional analysis of GIPR
dn expression by GIP/exendin-4 stimulation test. Reduced insulinotropic action of GIP but enhanced
insulinotropic action of exendin-4 in 11-week-old GIPR
dn transgenic pigs (tg) compared with nontransgenic control animals (wt). A: Serum
insulin levels of GIPR
dn transgenic (tg) and control (wt) pigs after intravenous administration of glucose (Glc)  GIP. B: Serum insulin levels
of GIPR
dn transgenic (tg) and control (wt) pigs after intravenous administration of glucose (Glc)  exendin-4 (Exe-4). C and D: Corresponding
serum glucose levels for the GIP (C) and exendin-4 (D) stimulation test. 0 min  point of Glc/GIP/exendin-4 administration. Data are means 
SE. *P < 0.05 vs. control; **P < 0.01 vs. control. E and F: Immunohistochemical staining of GIPR (E) and GLP-1R (F) in pancreas sections from
11-week-old GIPR
dn transgenic pigs (tg) and nontransgenic control animals (wt) does not provide evidence for differences in receptor abundance.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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dn does not
exhibit a toxic effect on pancreatic islets and further
suggest that pancreatic islet neogenesis is not disturbed.
Glucose control in GIPR
dn transgenic pigs deterio-
rates with increasing age. To monitor the long-term
consequences of GIPR
dn expression, a second collective of
animals was repeatedly investigated. First, an OGTT was
performed in 5-month-old (20  1 weeks) GIPR
dn trans-
genic pigs (n  5) and littermate controls (n  5)
originating from founder boars nos. 50 and 51. GIPR
dn
transgenic pigs exhibited elevated glucose levels (Fig. 4C)
as well as a distinct reduction of initial insulin secretion
after glucose challenge compared with their nontransgenic
littermates (Fig. 4D). In addition, peak insulin levels were
clearly reduced compared with controls. The AUC glucose
was 26% (P 
 0.05) larger (Fig. 4C), whereas AUC insulin
was 49% (P 
 0.01) smaller in GIPR
dn transgenic pigs (Fig.
4D). The latter ﬁnding suggests that, in contrast to 11-
week-old animals, the overall insulin secretion following
an oral glucose load is reduced in 5-month-old GIPR
dn
transgenic pigs and that their islets may undergo progres-
sive functional and/or structural changes. Additionally, an
IVGTT was carried out in 5-month-old (22.5  1.5 weeks)
GIPR
dn transgenic and control pigs (n  4 per group;
different collective of animals). Intravenous glucose toler-
ance (Fig. 5C), as well as insulin secretion (Fig. 5D), in
GIPR
dn transgenic pigs was similar to controls. However, a
tendency toward reduced intravenous glucose tolerance
and reduced insulin secretion in GIPR
dn transgenic pigs
was visible.
Next, we performed an IVGTT in 11-month-old (45  2
weeks) GIPR
dn transgenic pigs (n  5) and littermate
controls (n  4) from the same collective of animals used
for OGTT at 5 months of age. GIPR
dn transgenic pigs
exhibited a decelerated decline of blood glucose levels
(10% larger AUC glucose; P 
 0.05) (Fig. 5E), going along
with signiﬁcantly reduced insulin release (52% smaller
AUC insulin; P 
 0.05) (Fig. 5F). This observation corrob-
orated the suspicion that impaired GIPR function may
cause a general disturbance of insulin secretion and/or
alterations in islet structure and/or islet integrity over
time.
Impaired age-related expansion of pancreatic -cell
mass in GIPR
dn transgenic pigs. To clarify long-term
effects of GIPR
dn expression on the islets, we performed
quantitative stereological analyses of pancreata from
5-month-old and from 1- to 1.4-year-old GIPR
dn transgenic
pigs and controls. Pancreas weight did not differ between
GIPR
dn transgenic pigs and control animals in both age-
groups (Table 1).
Qualitative histological assessment revealed that pan-
creatic islet proﬁles of 5-month-old and 1- to 1.4-year-old
GIPR
dn transgenic pigs appeared to be smaller in size and
reduced in number (Fig. 6B and C). These ﬁndings were
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AUC:  28984  ±  1414  vs.  23856  ±  847;  p < 0.05    
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AUC:  6984  ±  716  vs. 14019  ±  1935;  p < 0.01
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FIG. 4. Oral glucose tolerance in 11-week-old and 5-month-old GIPR
dn transgenic pigs (tg) compared with nontransgenic littermates (wt). A and
C: Serum glucose levels; 0 min  point of glucose administration. B and D: Serum insulin levels. AUC glucose/insulin for transgenic pigs (red) and
wild-type pigs (blue). Data are means  SE. *P < 0.05 vs. control; **P < 0.01 vs. control; ***P < 0.001 vs. control. Note that in 11-week-old
transgenic pigs, there is a delay in insulin secretion leading to a signiﬁcant reduction of insulin secretion during the ﬁrst 45 min following oral
glucose load, although the total amount of insulin secreted over 120 min is not different from controls. In contrast, 5-month-old transgenic pigs
display not only delayed but also reduced insulin secretion. A high-quality digital representation of this ﬁgure is available in the online issue.
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5-month-old GIPR
dn transgenic pigs (n  4), the total
volume of -cells [V(-cell, Pan)] was diminished by 35% (P 

0.05) versus controls (n  4) (Fig. 6B). In 1- to 1.4-year-old
GIPR
dn transgenic pigs (n  5), the reduction of total
-cell volume compared with controls (n  5) was even
more pronounced (58%; P 
 0.01) (Fig. 6C). Reduced
-cell mass of young adult GIPR
dn transgenic pigs com-
pared with controls was conﬁrmed by islet isolation
experiments. The number of islet equivalents recovered
from pancreas samples of GIPR
dn transgenic pigs (n  3)
was reduced by 93% (P 
 0.05) as compared with litter-
mate controls (n  3) (supplementary Table 2).
In contrast, volume density (data not shown) as well as
the total volume of isolated -cells were not different
between GIPR
dn transgenic and control pigs, neither at 5
months of age (121  18 vs. 127  15 mm
3; P  0.883) nor
at 1–1.4 years of age (77  8 vs. 71  5m m
3; P  0.844).
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FIG. 5. Intravenous glucose tolerance in GIPR
dn transgenic pigs (tg) compared with nontransgenic controls (wt). A, C, and E: Serum glucose
levels; 0 min  point of glucose administration. B, D, and F: Serum insulin levels. AUC glucose/insulin for transgenic pigs (red) and wild-type pigs
(blue). Data are means  SE. *P < 0.05 vs. control; **P < 0.01 vs. control; ***P < 0.001 vs. control. Note that intravenous glucose tolerance (A)
and insulin secretion (B) are not altered in 11-week-old transgenic pigs. In 5-month-old transgenic pigs, a tendency of reduced insulin secretion
(D) is observed, while 11-month-old transgenic pigs display a signiﬁcantly reduced intravenous glucose tolerance (E) due to a signiﬁcantly
reduced insulin secretion (F). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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pancreatic -cell mass expansion in GIPR
dn transgenic
pigs, which is in line with previous evidence for a trophic
action of GIP on -cells in vitro (5–7).
Altered cellular composition of islets in GIPR
dn
transgenic pigs. To evaluate effects of GIPR
dn expression
on the volume densities of the various endocrine islet cells
and their total volumes, we performed detailed stereologi-
cal analyses of the pancreatic islets in all three age classes
investigated. In control animals, total volumes of -, -, -,
and pp-cells in established islets increased signiﬁcantly
with age (Table 1). In GIPR
dn transgenic pigs, a similar
age-dependent increase was seen for the total volumes of
-, -, and pp-cells. However, in comparison with controls,
the increase of total -cell volume of GIPR
dn transgenic
pigs was less pronounced from 11 weeks to 5 months of
age. Importantly, there was no further augmentation of
total -cell volume in 1- to 1.4-year-old GIPR
dn transgenic
pigs, demonstrating that impaired GIPR function inter-
feres with the physiological expansion of pancreatic
-cells. In addition, the fractional volume of -cells in the
islets was decreased, while that of - and -cells was
increased in 1- to 1.4-year-old GIPR
dn transgenic pigs.
However, the total volumes of these non–-cell popula-
tions were not different from those of age-matched control
pigs (Table 1).
Reduced proliferation rate of -cells in GIPR
dn trans-
genic pigs. To clarify the mechanism of impaired -cell
expansion in GIPR
dn transgenic pigs, we determined -cell
proliferation by double immunohistochemical staining for
insulin and the proliferation marker Ki67 in all three
age-groups. Indeed, -cell proliferation was signiﬁcantly
reduced by 60% (P 
 0.05) in 11-week-old GIPR
dn trans-
genic pigs (Fig. 7A and B). In addition, we performed
double immunohistochemical staining for insulin and the
apoptosis marker cleaved caspase-3 to evaluate a potential
impact of GIPR
dn expression on cell death in the -cell
compartment. Overall, the proportion of cleaved caspase-3
positive cells was very low, with no signiﬁcant difference
between GIPR
dn transgenic pigs and controls of all age
classes. However, there was a trend (P  0.075) of more
cleaved caspase-3 positive -cells in 1- to 1.4-year-old
GIPR
dn transgenic pigs as compared with age-matched
controls (Fig. 7C and D).
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FIG. 6. Immunohistochemistry for insulin and total -cell volume in the pancreas [V(-cell, Pan)] determined with quantitative stereological
methods. A–C: Representative histological sections of pancreatic tissue from a control (wt) and a GIPR
dn transgenic pig (tg); scale bar  200 m.
Unaltered total -cell volume in 11-week-old GIPR
dn transgenic pigs (n  5 per group) (A) but reduction of the total -cell volume in 5-month-old
(n  4 per group) (B) and young adult (1–1.4 years old) (n  5 per group) GIPR
dn transgenic pigs (C) compared with controls. Data are means 
SE. *P < 0.05 vs. control; **P < 0.01 vs. control. A high-quality digital representation of this ﬁgure is available in the online issue.
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This study established the ﬁrst transgenic large animal
model of impaired incretin function. The cDNA of the
human GIPR was mutated at the third intracellular loop,
where a deletion of eight amino acids (positions 319–326)
and a point mutation at position 340 was introduced. In
stably transfected Chinese hamster lymphoblast (CHL)
cells, GIPR
dn bound GIP with normal afﬁnity but failed to
increase intracellular cAMP levels. Thus, the GIPR
dn ex-
pressed in transgenic pigs is capable of ligand binding but
not of signal transduction (16) and competes with the
endogenous GIPR for GIP. Consequently, the insulino-
tropic effect of GIP is highly reduced but not completely
eliminated, mirroring the situation in human type 2
diabetes.
In view of the severe, early-onset diabetes of GIPR
dn
transgenic mice (16), we tested the oral and intravenous
glucose tolerance of young (11-week-old) GIPR
dn trans-
genic and control pigs and determined their pancreatic
-cell mass by quantitative stereological analyses. The
ﬁnding of reduced oral glucose tolerance associated with
delayed insulin secretion is in line with a disturbance of
the incretin effect. Reduced oral glucose tolerance in
GIPR
dn transgenic pigs is also consistent with previous
observations in Gipr
/ mice (14). Importantly, normal
intravenous glucose tolerance, insulin secretion, and un-
changed -cell mass in 11-week-old GIPR
dn transgenic pigs
strongly argue against a toxic effect of GIPR
dn expression.
The reasons for different outcomes in the GIPR
dn trans-
genic pig and the GIPR
dn transgenic mouse model remain
unclear but may be related to different methods of trans-
genesis (lentiviral transgenesis versus pronuclear DNA
microinjection) or different copy numbers and/or integra-
tion sites leading to different expression levels of the
transgene.
To evaluate long-term effects of GIPR
dn expression in
the pancreatic islets, we performed a longitudinal study of
a collective of animals, involving OGTTs and IVGTTs.
These revealed a progressive deterioration of glucose
control in GIPR
dn transgenic pigs, although none of our
transgenic pigs has developed fasting hyperglycemia up to
an age of 2 years. Quantitative stereological investigations
of pancreata from 5-month-old and from 1- to 1.4-year-old
GIPR
dn transgenic pigs showed a reduced pancreatic
-cell mass, which was conﬁrmed by quantitative islet
isolation experiments.
Quantitative stereological analyses of the pancreatic
islets demonstrated a marked increase of total -cell
volume from 11 weeks to 5 months (6.4-fold) and from 5
months to 1–1.4 years (1.6-fold) of age in control pigs. In
contrast, the expansion of total -cell volume in GIPR
dn
transgenic pigs was less pronounced between 11 weeks
and 5 months of age (4.3-fold), with no further increase in
1- to 1.4-year-old animals. These ﬁndings are explained by
a markedly reduced proliferation rate of -cells in 11-
week-old GIPR
dn transgenic pigs, a developmental stage
characterized by massive expansion of -cells in pigs (36).
Staining for cleaved caspase-3 did not show a signiﬁcantly
TABLE 1
Quantitative stereological analyses of the endocrine pancreas of GIPR
dn transgenic pigs (tg) and wild-type control pigs (wt)
Parameter
11 weeks
(n  5 wt, 5 tg)
5 months
(n  4 wt, 4 tg)
1–1.4 years
(n  5 wt, 5 tg) ANOVA
Means  SE Means  SE Means  SE Group Age Group 	 age
Pancreas weight (g)
Wild type 34.5  4.2 115.3  5.6 183.4  13.8 NS 
0.0001 NS
Transgenic 32.7  3.1 125.7  6.1 206.1  4.9
VV(-cell/islet) (%)
Wild type 69.8  2.2 89.0  1.5 90.2  1.2 0.0066 
0.0001 0.0024
Transgenic 70.8  1.3 87.0  1.2 76.4  3.2*
VV(-cell/islet) (%)
Wild type 14.1  1.2 5.0  0.8 5.0  0.7 0.0122 
0.0001 0.0008
Transgenic 12.2  0.7 6.5  0.7 13.8  2.3*
VV(-cell/islet) (%)
Wild type 13.5  2.8 4.3  0.8 2.2  0.6 NS 
0.0001 NS
Transgenic 13.0  1.0 5.5  0.9 5.8  0.9†
VV(pp-cell/islet) (%)
Wild type 2.7  0.7 1.8  0.3 2.8  0.8 NS 0.0355 NS
Transgenic 3.9  0.5 1.3  0.3 3.8  1.1
V(-cell/islet) (mm
3)
Wild type 168.7  29.5 1,088.2  82.0 1,694.6  251.7 0.0002 
0.0001 0.0024
Transgenic 152.1  17.1 664.1  74.5† 663.7  130.5*
V(-cell/islet) (mm
3)
Wild type 32.6  8.7 58.4  6.3 95.7  17.4 NS 
0.0001 NS
Transgenic 24.5  1.7 47.7  4.5 112.8  14.5
V(-cell/islet) (mm
3)
Wild type 26.6  3.9 49.5  6.1 36.8  6.3 NS 0.0014 NS
Transgenic 25.9  1.8 39.6  3.5 47.5  5.2
V(pp-cell/islet) (mm
3)
Wild type 6.0  1.8 20.7  2.9 52.4  12.6 NS 
0.0001 NS
Transgenic 8.2  1.7 9.3  2.1 30.3  7.9
Data were analyzed by the general linear models procedure (SAS Institute) taking the effects of group (wild type, transgenic), age (11 weeks,
5 months, 1–1.4 years), and the interaction group 	 age into account. For signiﬁcant effects of these factors P values are indicated in the last
three columns. In addition, signiﬁcant differences between groups within age classes are marked by: *P 
 0.01; †P 
 0.05; NS, not signiﬁcant.
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GIPR
dn transgenic pigs versus controls, although a trend
of higher numbers of cleaved caspase-3 positive -cells
was visible in 1- to 1.4-year-old GIPR
dn transgenic pigs.
This may suggest a contribution of apoptosis to the
reduction of total -cell volume in mature GIPR
dn trans-
genic pigs.
Due to the reduced volume fraction of -cells in the
islets of 1- to 1.4-year-old GIPR
dn transgenic pigs, the
relative volumes of - and -cells in the islets were
increased. However, since the islet volume was concomi-
tantly reduced, the absolute volumes of - and -cells were
not different between GIPR
dn transgenic and control pigs.
The numbers of animals investigated in our study are, in
part, smaller than in some rodent studies. However, due to
the large size of the pig, several blood-based parameters
could be measured repeatedly with short time intervals in
the same animals, providing an important advantage for
statistical analysis. Further, the stereological data of all
animals (n  28) were evaluated together by ANOVA,
demonstrating signiﬁcant group effects (Table 1) with P
values 
0.01 for many data/differences supporting our
core statements.
Interestingly, Gipr
/mice provided no evidence that
GIPR action is required for the maintenance of islet and
-cell integrity in vivo (15,37). These mice exhibited an
increase in relative -cell area referring to pancreas area
(37), leading to the conclusion that in vivo the function of
GIP is primarily restricted to that of an incretin (15).
However, the relatively mild phenotype of Gipr
/ mice
may result from compensatory mechanisms (15). Although
mice lacking both GIPR and GLP-1R exhibited more
severe glucose intolerance than the individual mutants
(38,39) these double mutant animals did not develop
diabetes, raising the suspicion of the existence of compen-
satory mechanisms other than the GIP/GLP-1 system (38).
The ﬁndings in GIPR
dn transgenic pigs suggest that, in
addition to its role as an incretin hormone, GIP is neces-
sary for the expansion of -cell mass and that its partial
loss of function cannot be fully compensated by hyperac-
tivation of the GLP-1/GLP-1R system.
In conclusion, GIPR
dn transgenic pigs resemble charac-
teristic features of human type 2 diabetic patients very
closely in the following ways: disturbed GIP function,
glucose intolerance, and reduced pancreatic -cell mass.
Moreover, GIPR
dn transgenic pigs may be an attractive
5 months 1-1.4 years 11 weeks 5 months 1-1.4 years 11 weeks
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
*
p=0.549
p=0.352
K
i
6
7
+
 
 
n
u
c
l
e
i
/
1
0
5
 
n
u
c
l
e
a
r
 
p
r
o
f
i
l
e
s
0
10
20
30
40
p=0.313
p=0.336 p=0.075
C
a
s
p
3
+
 
n
u
c
l
e
i
/
1
0
5
 
n
u
c
l
e
a
r
 
p
r
o
f
i
l
e
s
A
B
C
D
FIG. 7. -Cell proliferation and apoptosis. A and C: Representative histological sections doublestained for insulin (blue) and Ki67 (brown) (A)
or for insulin (light brown) plus cleaved caspase-3 (dark blue; see arrow) (C). B and D: Determination of the number of Ki67 (B) and cleaved
caspase-3–positive -cells (D). Wild type: blue bars, transgenic: red bars. Wild type: n  5, transgenic: n  5 for 11-week-old and 1- to 1.4-year-old
pigs; wild type: n  4, transgenic: n  4 for 5-month-old pigs. Data are means  SE. *P < 0.05 vs. control; scale bar  20 m. Note the signiﬁcantly
(P < 0.05) reduced -cell proliferation rate in 11-week-old GIPR
dn transgenic pigs. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
TRANSGENIC PIGS WITH IMPAIRED GIP FUNCTION
1236 DIABETES, VOL. 59, MAY 2010 diabetes.diabetesjournals.organimal model for the development and preclinical evalua-
tion of incretin-based therapeutic strategies (40). Another
potential application of GIPR
dn transgenic pigs is the
development of novel techniques for dynamic in vivo
monitoring of pancreatic islet mass (41). Due to their size
and close physiological and anatomical similarities to
humans (42), pigs represent attractive animal models for
translating novel therapeutic and diagnostic principles
into clinical practice.
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